
News|Articles|February 13, 2019
Elzonris for Blastic Plasmacytoid Dendritic Cell Neoplasm
Author(s)Drew Boxler
Advertisement
ELZONRIS (tagraxofusp-erzs, Stemline® Therapeutics)
Indications: Treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older
Dosage: Intravenously at 2mcg/kg over 15 mins once daily on days 1 & 5 of a 21-day cycle
- First cycle recommended in inpatient setting, subsequent cycles either inpatient or other appropriate outpatient setting
Contraindications: None
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Now Authorized to Independently Prescribe Buprenorphine
2
Diet and Insulin Management Technology Show Most Consistent Benefits for Type 1 Diabetes
3
Pharmacists Step Up in Treating Cardiometabolic Conditions
4
How TrumpRx Is Bringing Unprecedented Change to the Drug Supply Chain
5



































































































































